- Home
- TAL vs XENE Comparison
TAL vs XENE Comparison
Compare TAL & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAL | XENE |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.2B |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TAL | XENE |
|---|---|---|
| Price | $9.68 | $53.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $11.15 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $22.97 | N/A |
| Revenue Next Year | $17.08 | $2,496.48 |
| P/E Ratio | $23.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.52 | $30.00 |
| 52 Week High | $13.37 | $62.91 |
Technical Indicators
Market Signals| Indicator | TAL | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 43.63 |
| Support Level | $9.52 | $52.90 |
| Resistance Level | $11.58 | $59.43 |
| Average True Range (ATR) | 0.36 | 1.52 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 10.42 | 36.21 |
Price Performance
Historical ComparisonAbout TAL TAL Education Group
TAL Education Group is a leading learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.